Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
June 27, 2019 04:11 PM

House Dems question Gilead's HIV drug donations

Steven Ross Johnson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Wikimedia Commons/Jeffrey Beall

    Democratic members of the House Oversight Committee want Gilead Sciences to reveal whether its decision to donate more than 2 million doses of its HIV-prevention medication Truvada was connected to an ongoing patent dispute.

    In a letter sent Wednesday to Gilead CEO Daniel O'Day, House Oversight and Reform Committee Chair Rep. Elijah Cummings (D-Md.) asked whether the company's decision to donate Truvada was in some way connected to the company's dispute over its patent for the drug.

    "Gilead has taken the position that the government's patents are not valid," the lawmakers wrote. "We would like to understand whether these patents played any role in the negotiations between the company and (HHS), and whether Gilead has otherwise engaged in negotiations with the U.S. government regarding these patents."

    HHS announced in May that Gilead agreed to donate up to 2.4 million doses of its pre-exposure prophylaxis, or PrEP, medication that the agency estimated would cover up to 200,000 individuals a year for up to 11 years. HHS Secretary Alex Azar stated the agreement was the "result of discussions between the Trump administration and Gilead Sciences"

    Azar called Gilead's donation a "major step" toward the Trump administration's effort to end the HIV epidemic in the U.S. by 2030.

    Oversight committee Democrats asked Gilead to provide all documents and communications between the company and the federal government regarding the donation of Truvada, U.S. patents related to PrEP, and its series of annual price increases since 2012. Since 2012 the cost of Truvada has gone from an average list price of $1,391 per month to $2,100 a month. The deadline is July 26.

    Gilead's patents for Truvada as a PrEP medication have been a hot topic for patient advocates. They argue the drugmaker reaped billions of dollars from years of market exclusivity due to lack of government enforcement. In 2018 alone, Truvada generated $3 billion in revenue, according to the company's financial statements.

    Cummings and Sen. Debbie Stabenow (D-Mich.) on June 18 sent a letter requesting that the Government Accountability Office look into reports that Gilead may have infringed on government-owned patents involving Truvada for PrEP.

    "If true, this would mean that a private entity has generated billions of dollars in revenue over several years while infringing on government-owned intellectual property, and that the government either failed to detect the infringement or was aware and failed to prevent it," lawmakers wrote.

    Critics say Gilead's market exclusivity of Truvada for PrEP made the drug more cost prohibitive for individuals at greatest risk of HIV infection and limited their access to the treatment. Only 90,000 prescriptions for PrEP were filled in 2015 among the estimated 1.1 million Americans who would benefit from taking the medication, according to the Centers for Disease Control and Prevention's most recent figures. Among those who filled prescriptions, only 14,000 were filled by African-American and Latino adults, even though they make up 800,000 of the 1.1 million at risk.

    The rising cost of Truvada was the subject of an oversight committee hearing in May, where O' Day argued the drug's price was tied to the costs of research and development, which totaled around $1 billion.

    "Gilead bore the risk and the vast majority of the cost of research and clinical studies to demonstrate Truvada's efficacy and safety as part of combination HIV therapy," O'Day said. "Our well-supported view is that the U.S. government does not hold valid patents on the use of Truvada for pre-exposure prophylaxis ("PrEP"), nor does it hold any patent for Truvada itself."

    Gilead initially marketed Truvada in 2004 as a treatment for HIV and eventually scored FDA approval in 2012 to sell it as PrEP.

    But critics point out much of the research that led to the discovery of Truvada as a pre-exposure prophylactic was publicly funded and conducted by the CDC, which applied for a patent for that use in 2006 that was eventually awarded in 2015.

    Patient advocates such as the PrEP4All Collaboration have called for the federal government to begin enforcing its patent on Truvada for PrEP, but so far it has not taken action.

    "Members of Congress—the American people have invented a way to end the HIV epidemic, and today, we look to you, to ensure that every single person in this country can protect themselves from this plague," said Dr. Aaron Lord, co-founder of Prep4All, during the May committee hearing.

    Gilead did not respond to requests for comment Thursday.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    abortion-pill-misoprostol-legal
    Abortion pill case advances to appeals court, on course to Supreme Court
    young doctor medical resident
    Federal physician recruitment program at risk
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing